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ANTIMICROBIAL PEPTIDES AS A
MEANS TO COMBAT ANTIBIOTIC
RESISTANCE
The rise of antibiotic resistance has
emphasized the shortcomings in antibi-
otic drug development (Boucher et al.,
2013). The move from biological based
discovery methods to chemical approaches
to identify candidates has left the antibi-
otic pipeline painfully dry (Lewis, 2013).
The paucity of compounds that are effec-
tive against antibiotic resistant pathogens
has led to great interest in antimi-
crobial peptides (AMPs) as potential
solutions to the rise of resistant organ-
isms (Hancock and Sahl, 2006; Fox,
2013). AMPs are short (5–50 amino acid)
peptides that are produced by virtu-
ally all organisms as part of an innate
immune system. There are 2,398 AMPs
that have been reported (Antimicrobial
Peptide Database—September 2013) and
over 80% are cationic AMPs (CAMPs).
Most positively charged AMPs inter-
act with anionic bacterial membranes
(Schmidtchen andMalmsten, 2013) which
leads to a rapid breakdown in mem-
brane function and subsequent cell death
(Wimley, 2010). It is this mechanism of
action that is of interest as it should
be difficult for bacteria to develop resis-
tance against lethal concentrations of
CAMPs.
However, many AMPs have poor drug-
like properties and questions remain
about that their ultimate utility as antibi-
otics (Brogden and Brogden, 2011). Great
strides have been made in improving the
protease stability; pharmacokinetics and
therapeutic profile of peptide drugs and
these methods have been used to improve
the drug-like properties of AMPs. Despite
the significant developments that have
been made to advance AMPs through the
clinical pipeline there has yet to be an
approved AMP therapeutic (Vila-Farres
et al., 2012). Clearly there is an ongoing
need for additional AMP candidates as a
tool in the fight against antibiotic resistant
bacteria.
DISCOVERY OF SYNTHETIC AMPs
Many groups are turning to non-natural
sources to discover the next generation
of AMPs. These efforts are focused on
computational design of AMPs or by
screening large libraries of peptides for
new candidates. There have been signif-
icant advances in computational design
of AMPs and progress continues in this
field, illustrated by the recent work of
Deslouches et al. (2013). However, these
studies are guided by rules learned from
natural AMPs and could be limiting in
terms of designing peptides that function
like natural AMPs with all of their inherent
strengths and weaknesses. Other groups
have used peptide discovery systems to
screen large libraries of peptides with the
aim of identifying synthetic AMPs and
potentially novel classes of AMPs. Display
technologies, such as phage display, are
capable of producing large libraries of pep-
tides (∼107 peptides) that can be used
to discover AMPs (Huang et al., 2012).
However, display techniques can be diffi-
cult to adapt to whole bacteria screening
and require multiple rounds of selection to
identify peptides with activities similar to
natural AMPs.
A promising approach to discover
antibacterial candidates is to screen
a target bacterium against a peptide
library arrayed on a solid surface. This
approach uses two different types of pep-
tide libraries: in situ synthesized peptide
arrays and libraries of peptides pre-
pared as spotted peptide microarrays.
Seminal work in the use of in situ pep-
tide microarrays for AMP development
was demonstrated for small libraries
of variants of natural AMPs (Hilpert
et al., 2005, 2007, 2009; Hilpert and
Hancock, 2007). In this method, hundreds
to thousands of peptides are synthe-
sized on a nitrocellulose membrane,
then chemically cleaved into micro well-
plates where there are then tested for
activity. In contrast to this approach,
spotted peptide microarrays are pre-
pared by the synthesis of thousands to
tens of thousands of peptides, which are
printed on glass slides using standard
microarray printing technology. Peptide
microarrays have been used for ligand
discovery by many groups and assays
have been developed to screen whole cells
against immobilized ligands (Papp et al.,
2012).
DISCOVERY OF ANTIBACTERIAL
PEPTIDES DIRECTLY ON PEPTIDE
MICROARRAYS
We have recently introduced an activity
based assay that enables the selection of
peptides with antibacterial activity directly
on peptide microarrays (Domenyuk et al.,
2013). In this assay, the target bacteria
is labeled with an internal dye that fluo-
resces while the cell is metabolically active
(e.g., Cell-Tracker Orange) and the exte-
rior of the bacteria (outer membrane for
Gram-negative or peptidoglycan layer for
Gram-positive bacteria) is labeled with an
amine-reactive dye, such as AlexaFluor-
555 (Figure 1A). Fluorescently labeled
www.frontiersin.org December 2013 | Volume 4 | Article 402 | 1
Diehnelt Peptide array discovered antimicrobial peptides
FIGURE 1 | (A) Activity based bacterial screening to identify peptides that
bind and those that kill a specific pathogen. AF, AlexaFluor-555; CTO,
Cell-Tracker Orange. (B) Number of peptides based on net charge for AMPs
described in the AMP Database, the 30,000 peptides used in spotted peptide
arrays, and the 330,000 peptides used in the first generation in situ peptide
array produced in our laboratory.
bacteria are then screened against a spotted
peptide microarray of 10,000, 20 amino
acid long peptides to identify peptides that
bind the bacteria and those that kill the
bacteria. Peptides that bind but do not
kill the bacteria produce two fluorescent
colors, while those that bind the bacteria
and disrupt the membrane produce one
signal. Using this system, we were able to
identify peptides that inhibited growth of
both Gram-positive and Gram-negative
bacteria with minimum inhibitory
concentrations (MIC’s) in the 20μM
range.
This approach has several important
advantages as a source of antibacterial
peptides. First, the system can be used
to screen a wide variety of bacteria.
Laboratory strains or clinical isolates can
be easily labeled and do not require
genetic modification to express a fluores-
cent or colorimetric indicator. The label-
ing procedures are robust and effective for
Gram-positive and Gram-negative bacte-
ria. Second, the method is rapid; bacte-
ria can be labeled, screened, and analyzed
in the same day. Additionally, the con-
venience of solid phase synthesis enables
the incorporation of non-natural amino
acids, such as D-amino acids or β-amino
acids, into peptide libraries, enabling the
direct screening of protease stabilized
peptides. The in vitro assay format is
very flexible in terms of the screening
conditions, buffers, sera or media that
can be used. Finally, peptide libraries
can be designed without the inherent
biases present in natural AMPs, potentially
enabling the discovery of active peptides
that function with novel mechanisms of
action.
FUTURE DIRECTIONS FOR PEPTIDE
ARRAY BASED
DISCOVERY—SELECTION OF PEPTIDES
THAT SPECIFICALLY TARGET AMP
RESISTANT BACTERIA
In our opinion, the future of array based
AMP discovery lays in the selective tar-
geting of antibiotic and AMP resistant
bacteria over normal flora. This could
be possible due to the convergence of
several parallel avenues of technical and
scientific development. Recently, robust
methods for the in situ synthesis of
peptide microarrays with medium den-
sities, >103–104peptides (Loeffler et al.,
2012; Price et al., 2012), and those
with much higher densities, 105–106 pep-
tides per array (Legutki, submitted) have
been reported. This significantly expands
the peptide sequence space that can be
explored in a single experiment. This
could be an especially important devel-
opment in the search for peptides that
are active against either intrinsically AMP
resistant bacteria, such as Burkholderia
cepacia complex (Loutet and Valvano,
2011), or those that acquire AMP resis-
tance after treatment with CAMPs (Anaya-
López et al., 2013; Fernández et al., 2013;
Napier et al., 2013; Pelletier et al., 2013;
Shireen et al., 2013). Acquired AMP resis-
tance generally involves membrane mod-
ifications that increase the charge of the
surface of the bacteria that prevents bind-
ing of CAMPs to the cell surface. This
potentially is a troubling development as
the vast majority of AMPs (>80%) discov-
ered to date are cationic and there is some
evidence that acquired resistance for one
CAMP can extend to host AMPs (Napier
et al., 2013). The latter report argues for
the selection of AMPs that are not related
to natural ones. For these pathogens, it is
possible that neutrally charged or anionic
AMPs will be effective against AMP resis-
tant bacteria that have membranes modi-
fied with cationic groups.
It is here that the recent advances in in
situ peptide array synthesis could become
important. As peptide libraries can be
designed with a more even distribution of
charged peptides, large numbers of neu-
tral and anionic peptides can be screened
against a resistant pathogen. This is illus-
trated in Figure 1B, where the number
of anionic, neutral, and cationic peptides
is plotted for: the peptides in the AMP
database, the 30,000 peptides we have
used in our spotted peptide libraries, and
the 330,000 peptides of our recent high-
density in situ peptide arrays. As can be
seen, peptide arrays offer the opportu-
nity to screen thousands to over 130,000
neutral and anionic peptides in a single
experiment. It is possible that by screen-
ing both the AMP resistant and sensitive
phenotype of a pathogen against this array,
one could identify reduced charge peptides
that inhibit the resistant phenotype with
little effect on the sensitive phenotype. It
is also possible that a peptide that selec-
tively targets the AMP resistant bacteria
would have a much narrower spectrum of
activity toward normal flora. The selective
targeting of the pathogen should help limit
the spread of resistance to other species in
the microbiome and maintain normal
flora. It is likely that as the understand-
ing of the host microbiome increases,
the importance of targeted therapeutics
will be even more evident. The use of
molecular methods to quickly identify
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bacteria from clinical specimens is rapidly
being adopted and should enable physi-
cians to match a targeted antibiotic with
the correct pathogen. Advances in pep-
tide array discovery assays could provide
a system to develop pathogen-specific
antibiotics (Casadevall, 2009; Lemon et al.,
2012) and lead to the discovery of the first
generation of targeted antibiotics.
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